Celltrion Healthcare sells Remsima exclusively in Libya and Tunisia
As winning the bidding competition for infliximab biosimilar in the Middle Eastern countries, Celltrion Healthcare started to exclusively sell ‘Remsima(generic name: infliximab),’ a biosimilar for the treatment of autoimmune disease.
Celltrion Healthcare succeeded in winning a tender against the...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
